Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Immunos Therapeutics AG has one pending office action in Biotechnology & Pharmaceuticals. One examiner and one art unit are associated with the active matter. LANDSMAN, ROBERT S is the busiest examiner, with one pending matter, so the current prosecution record is concentrated in a single examination channel.
The available profile supports a targeted review of the office action and the assigned examiner’s requirements. There is no indication of parallel activity that would require harmonizing positions across multiple art units. Counsel can focus on preserving the desired claim scope while addressing the single biotechnology and pharmaceutical prosecution issue identified here.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LANDSMAN, ROBERT S | 1 | 81.4% | +13.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18681073 | PHARMACEUTICAL COMPOSITIONS COMPRISING HLA FUSION PROTEINS | LANDSMAN, ROBERT S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18681073 | PHARMACEUTICAL COMPOSITIONS COMPRISING HLA FUSION PROTEINS | LANDSMAN, ROBERT S | — |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18681073 | PHARMACEUTICAL COMPOSITIONS COMPRISING HLA FUSION PROTEINS | LANDSMAN, ROBERT S | 1647 | §112Other | Non-Final OA | — | Pending | Feb 05, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialImmunos Therapeutics AG has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Robert S Landsman has the most, with 1 of Immunos Therapeutics AG's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
